This review surveys the diversity of natural products derived from terrestrial plants, microorganisms, marine organisms and fungi and utilised in the treatment of various diseases.
Introduction
Natural products (NPs) obtained from plants, animals, marine organisms or micro-organisms are shaped by evolution. Through evolutionary time, the biosynthetic ‗engine' of nature has produced a myriad of NPs of huge chemical diversity and often distinct biological properties.
Such NPs are often stereochemically complex molecules annotated with diverse functional groups, interacting with high specificity with biological targets. These characteristics make them valuable as health products or structural templates for drug discovery.
For centuries, mankind has sought to fight disease and improve ‗quality of life'. As early as 1806, a German pharmacist, Friedrich Wilhelm Adam Serturner, reported the isolation of morphine 1, named after Morpheus, the Greek god of dreams [1] [2] . This work paved the way for the discovery of many other natural products including Strychnine 2, Atropine 3, Colchicine 4 and others [3] . Since then natural products have remained a constant source of discovery of new secondary metabolites with medicinal significance. 
Morphine
More than half of currently available drugs are natural compounds or are related to them [4] , and only 36% of the 1073 small molecule approved drugs for all diseases [13] are considered as truly synthetic. Approximately 68% of anti-infectives (antibacterial, antifungal, antiparasitic and antiviral compounds) are classified as naturally-derived or inspired, while 79 .8% of compounds in cancer treatment fall in this category. New structurally diverse natural compounds isolated from plant sources [5] [6] have been considered as prototypes, leads or heads of series and their later structural modification has generated compounds with pharmacological activities and real therapeutic potential [7] [8] [9] [10] [11] [12] . The continued search for new NPs extracted from living organisms is strongly driven by the continued evolution of infective agents and the expanding scope of medical and therapeutic targets [14] [15] [16] [17] .
Natural products as anticancer agents
In the field of anticancer drug therapy, a number of important new compounds in clinical use have been obtained either directly or indirectly from natural sources, either by structural modification of natural compounds, or by the synthesis of new compounds using natural compound as models.
The use of plant material for anticancer therapy was initiated with the isolation of two alkaloids, Vinblastine 5 and Vincristine 6, from the Madagascar periwinkle, Catharanthus roseus G. Don (Apocynaceae). These two agents were used for the treatment of cancer by virtue of their ability to inhibit mitotic cell division [18] . They irreversibly bind to tubulin, thereby blocking cell multiplication and eventually causing cell death, and have shown efficacy against lymphocytic leukaemia. A series of semi-synthetic analogues of these two molecules with higher therapeutic indices have been developed. Navelbine or Vinorelbine (VRLB) 7 and Vindesine (VDS) 8 showed activity against leukaemia's, lymphomas, advanced testicular cancer, breast cancer, lung cancer and Kaposi's sarcoma when treated in combination with other chemotherapeutic drugs. Many other semi-synthetic derivatives are in clinical development. Vinflunine, a novel bifluorinated vinca alkaloid obtained from its parent compound Vinorelbine, has been approved as an anticancer drug for the treatment of bladder cancer [19] . 
Vinflunine
Camptothecin (CPT) 10, a quinoline alkaloid with topoisomerase-I inhibitor activity isolated from Camptotheca acuminate, induces cell death by DNA damage [20] . However, this compound exhibited low aqueous solubility and severe toxicity. To overcome these limitations, a panel of CPT analogues were synthesized. Some of the most promising analogues, including topotecan 11, irinotecan 12, (CPT-11), 9-amino camptothecin (9-AC), lurtotecan and rubitecan, effectively inhibiting DNA topoisomerase-I, a critical enzyme in DNA replication and transcription [21] . Other semi synthetic CPT derivatives include Karenitecin 13, which has been used in Phase III trials against ovarian cancer and phase II trials against Brain Cancer, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Oncolytic Drugs and Solid Tumours [22] [23] , and Diflomotecan 14, in Phase II trials to treat small cell lung cancer (SCLC) [24] . Gimatecan 15,
an oral topoisomerase I inhibitor, has been reported in Phase II against advanced epithelial ovarian, fallopian tube, peritoneal cancers and recurrent glionlastoma [25, 26] . Elomotecan 16, an inhibitor of topoisomerase I and II, is in Phase I trials against colon, breast and prostate cancer [27] . Clinical phase I trials have been conducted on DRF 1042 17 for the treatment of solid tumours [28] . 
DRF1042
Phodophyllotoxin 18, obtained from Podophyllum peltatum, is another important anti-cancer compound [29] . Some 30 years after its discovery, it was demonstrated that this compound bound irreversibly to tubulin [30] and therefore had potential as an anticancer agent. 
Podophylotoxin
The discovery of paclitaxel (Taxol, 21) from the bark of the Pacific Yew, Taxus brevifolia Nutt (Taxaceae) is a dramatic example of successful natural product drug discovery. An extract of T. brevifolia was shown to possess anticancer properties in 1963, and the active component paclitaxel (Taxol) was subsequently isolated and characterized [33] [34] . Paclitaxel was reported to bind irreversibly with β-tubulin, promoting microtubule stabilization [35] and cellular apoptosis [36] . Paclitaxel has been used in the treatment of several types of cancers, including ovarian and breast cancers and non-small cell lung tumours [37] . The structure of Paclitaxel is highly complex and it is unlikely that combinatorial chemistry would have led to its discovery. However, the structural complexity of molecule has made it a good candidate for combinatorial modifications to produce a panel of analogues [38] . Temodar (temozolomide) for patients with metastatic melanoma, or to establish the efficacy of the drug combination for treatment metastatic melanoma [50] [51] . 
BMS-188797
A large number of other bioactive compounds, showing activities which might be appropriate for drug use, have been isolated from plant sources. Several are currently in clinical trials or preclinical trials or undergoing further investigation ( Table 1) . 
KRX-0601
Anticancer agents have also been isolated from marine sources. Bergman first isolated two nucleosides, spongouridine 75 and spongothymidine 76, from sponges [155] [156] [157] . These are considered as the precursors of all nucleoside drugs including cytosine arabinoside (Ara-C 77) [158] . Recently, much attention has been focussed on marine organisms due to their extensive biodiversity [159] . Structurally unique secondary metabolites have been isolated and identified from marine organisms and many of the candidates have shown prominent biological activities [160] [161] . These include Aplidine 78, isolated from the Mediterranean tunicate, Aplidium albicans, which has shown activity against certain tumor types (medullary thyroid carcinoma, renal carcinoma, melanoma, and tumours of neuroendocrine origin) [162] .
Agelasphins 79 (new glycosphingolipids) were isolated as antitumor agents from Agelas mauritianus [163] . Bryostatin I 80, isolated from the bryozoan (Bulgula neritina), binds to phorbol ester receptors. The binding of bryostatin I to its receptors down-regulates protein kinase C isoforms in various tumor cells, leading to inhibition of growth, alteration of differentiation and/or cell death [164] . This compound was granted orphan drug status by the [165] , is a microtubule-stabilizing drug [166] [167] . Halichondrin E7389 82, a derivative of halichondrin B isolated from Halichondria okadai, was found to inhibit tumor cell proliferation in association with the G 2 /M arrest and microtubule polymerization [168] . Spisulosine 83, isolated from Spisula polynyma, has demonstrated antiproliferative activity against various human cancer cell lines (colon, gastric, pancreas, pharynx, and renal tumours), and inhibits growth of human renal tumours, melanoma and prostate tumours [169] [170] . 
Arbanocytidine

Spisulosine
In the year 2010, seven drugs were approved as anti-tumor agents, five of which are natural product-based. These include Romidepsin 84, a histone deacetylase inhibitor (HDAC), which is an unmodified microbial natural product [171] [172] [173] [174] . The other four are derivatives of natural products and include Vinflunine (semi synthetic derivative of vinca alkaloids), andCabazitaxel (semi synthetic derivative of taxol). Mifamurtide 85, is a derivatized muramyl dipeptide and has been approved for the treatment of osteosarcoma [175] .
Fingolimod is derived from an old fungal metabolite known as myriocin [176] [177] . 
Mifamurlide
Other natural anticancer products that have been subjected to structural modifications, in order to develop improved anticancer drugs, are Puromycin, Mitomycin C, Dactinomicin, Doxorubicin, Daunorubicin, Bleomycin, Mitramicin, Masoprocol and Resveratrol [178] [179] .
Although natural products have contributed significantly in the discovery of anti-cancer agents, no safe and effective anti-cancer drug has yet been developed from a natural product lead compound.
Natural products as anti-infective agents
Anti-bacterial
Infectious diseases are currently the second major cause of death worldwide and third leading cause of death in economically advanced countries [180] . β-Lactams, which inhibit the final (Table 2) . Semi-synthetic derivatives of many of these has been approved as drugs, including
Tigecycline 87, which is a semi-synthetic product of chlortetracycline isolated from Streptomyces aureofaciens. Tigecycline exhibited antibacterial activity typical of other tetracyclines, but with more potent activity against tetracycline-resistant organisms [184] .
Telithromycin 88 is a semi-synthetic derivative of the 14-membered macrolide, Erythromycin A, isolated from Saccharopolyspora erythraea, and retains the macrolactone ring as well as a D-desosamine sugar moiety [185] . Other semi synthetic derivatives of Erythromycin that are under clinical development include Cethromycin [186] , EP-420 [187] and BAL-19403 [188] . 
Telithromycin
Other antibacterial agents under clinical development include Ceftaroline acetate 89, under
Phase II clinical trials for the treatment of cSSSIs and CAP , which shows efficacy against the penicillin-resistant S. pneumonia [189] . Clinical trials with Tebipenem pivoxil 90, an oral carbapenem antibiotic, have been conducted by Meiji Seika in Japan, for treatment of otolaryngological/respiratory infections [190] . Tomopenem 91 [191] , used for treatment of common nosocomial infections and PZ601 92 [192] , used against MRSA and Pseudomonas aeruginosa, have been evaluated in Phase II trials. ME1036 (CP5609) 93, a DHP-1-stable parenteral carbapenem, has excellent in vitro activity against multidrug-resistant (MDR) staphylococci and Enterococcus faecalis. The related compound, Sulopenem 94, is in Phase I trials [193] . Faropenem daloxate 95 is a penem-type β-lactam in the treatment of bacterial sinusitis (BS), chronic bronchitis (CB), CAP and uncomplicated SSSIs [194] . 
Televancin
The indiscriminate use of antibiotics has led to the development of multi drug-resistant pathogens. More than 80% of S. aureus strains worldwide are resistant to Penicillin [194] and
Methicillin [195] . Efforts are being made to search for the reliable methods to control vancomycin-resistant Enterococci (VRE), vancomycin-resistant Streptococcus aureus (VRSA) and methicillin-resistant S. aureus (MRSA). Thus there is a need to design and develop novel highly effective anti-infective agents in general and anti-mycobacterials in particular. Plant derived antibacterials have always been a source of novel therapeutics.
Plants are known to produce enormous variety of small molecule antibiotics, generally classified as phytoalexins. However, most of these small molecules have weak antibiotic activity, several orders of magnitude lower than common antibiotics produced by bacteria and fungi. There is a long list of herbs known to be used as treatments of infectious diseases, including Acacia, Garlic, Turmeric, Neem, Ginger, Clove, Plum and Pomegranate etc.
Extracts from most of these herbs have been screened in the search for safer and more effective antibacterial agents [196] [197] [198] [199] [200] [201] .
Anti-fungal compounds
Invasive fungal infections are increasingly implicated in the deaths of severely immunocompromised patients [202] . Candida species are, at present, ranked as the third most frequently isolated blood stream pathogens. Although C. albicans remains the principal etiologic agent of candidiasis, several other Candida species, which tend to be resistant to the commonly used antifungal drugs, have emerged as significant opportunistic pathogens. Highlevels of antimicrobial resistance are often associated with microbial biofilms.
Natural products play an important role in the development of antifungal strategies. Polyene antibiotics are naturally occurring polyketides isolated from various Streptomyces species that display broad spectrum antifungal activity. Their mechanism of action involves complexation with ergosterol and destabilization of the fungal cell membrane, which causes increased membrane permeability and fungal cell death. Amphotericin B is commonly used to treat fungal infections but is known to have significant toxicity, leading to mild clinical responses including chills, fever, headache, nausea and vomiting, and (more seriously) dose-limiting nephrotoxicity [203] . A number of other antifungal agents are in clinical development, including SPK-843 99, in phase III trials for treatment of systemic mycosis [204] and PLD-118 (Icofungipen) 100, a NP-derived synthetic compound in phase II clinical trials [205] .
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Only one antifungal drug has been approved in the 2006 to 2010 period. This was the echinocandin derivative anidulafungin 101. One of the reasons for the low number of new antifungal drugs is due to the fact that, as eukaryotes, humans and fungi share some of the same molecular processes;there is therefore always the risk that a compound toxic to the fungal cells will be equally toxic to the host cells. 
Anidulafungin
Plants have also been a good source of antifungal agents. A number of compounds isolated from plants, including dimethyl pyrrole, hydroxydihydrocornin-aglycones and indole derivatives, are reported to have antifungal activities [206] . However, development of useful antifungal drugs from these compounds has not yet been successful.
Anti-viral compounds
Viral diseases such as HIV, hepatitis B and C (HB/CV), Ebola, influenza, dengue fever and yellow fever are some of the greatest health risks known to humans [207] . Antiviral drugs have also relied heavily on natural products as drugs and/or leads. Isolation of Spongouridine and spongothymidine led to the discovery of the anti-HIV drug AZT 102, and most commonly used antiviral drugs have been developed from these two nucleosides. Among other promising compounds being evaluated for treatment of HIV is PA-457 103, a semisynthetic derivative of the plant triterpenoid betulinic acid [208] . Viramidine (ribamidine)
104 is being evaluated in Phase III clinical trials in combination with pegylated interferon α-2b for treatment of chronic HCV. Viramidine is a prodrug that is converted to ribavarin by adenosine deaminase in the liver [209] [210] . 4-Methylumbelliferone 105 is a naturally occurring coumarin that has been tested in Phase II development for the treatment of HBV and HCV [211] . 1,5-DCQA (1,5-di-caffeoylquinic acid) 106, a HIV-1 integrase inhibitor extracted from Inula britannic, has been reported to be effective for treatment of HIV/AIDS and hepatitis B [212] . 
Laninamavir
Thus in contrast to anti-bacterial and anti-fungal drugs, antiviral drugs constitute a greater percentage derived from natural products. 
Anti-malarial compounds
Arterolane
Artether is currently used only as a second line drug in severe cases of malaria but is increasingly being used against vivax malaria. Arterolane 116, a trioxolane modelled on artemisinin 65 pharmacophore, was launched as a drug for the treatment of malaria by Ranbaxy in combination with piperaquine with the trade name of synriam.
Conclusion
The process of transforming herbal remedies into drugs was initiated in the early nineteenth century, but has been relatively slow. The advent, over the last four decades, of molecular It is widely believed that is the earth's pangenome harbours and enormous diversity of natural resources, only a small portion of which has yet been explored. So it therefore assumed that natural bio-resources will continue to provide bioactive compounds as leads for the further development of new and better drugs, and that this route will be more effective than the design of newcompounds by de novo synthesis.
